GW Pharmaceuticals Takes A Step Toward Diversifying

GW Pharma Takes A Step Toward Diversifying

Flickr / Interiorrain / (CC BY-ND 2.0)

Being a one-trick pony can always prove risky. This rationale seems to have dawned on GW Pharmaceuticals PLC- ADR, a biopharmaceutical company specializing in prescription cannabinoid medicine.

The company announced Tuesday positive top-line results from a mid-stage placebo-controlled study of a proprietary combination of tetrahydrocannabinol, or THC, and cannabidiol, or CBD, for treating glioblastoma multiforme, or GBM. This is seen as the company’s baby steps in diversifying its portfolio, having already ventured deep into epilepsy treatment with its Epidiolex.

View Original Article Here

Repost is the designation for articles collected from the Internet whose content may interest our readers. These articles are not written by our staff and they do not necessarily reflect our views.

Related posts